“Triple Negative Breast Cancer Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Triple Negative Breast Cancer Market.
The Triple Negative Breast Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Triple Negative Breast Cancer Pipeline Report:
-
Companies across the globe are diligently working toward developing novel Triple Negative Breast Cancer treatment therapies with a considerable amount of success over the years.
-
Triple Negative Breast Cancer companies working in the treatment market are Sichuan Kelun-Biotech Biopharmaceutical, Akeso Biopharma, ProLynx, ModernaTX, Inc., OncoTherapy Science, Phoenix Molecular Designs, Abbisko Therapeutics, BioLite, Inc., Zenith Epigenetics, HiberCell, Inc., Infinity Pharmaceuticals, G1 Therapeutics, Inc, Jiangsu HengRui Medicine Co., Ltd, Shanghai Henlius Biotech, and others, are developing therapies for the Triple Negative Breast Cancer treatment
-
Emerging Triple Negative Breast Cancer therapies in the different phases of clinical trials are- SKB264, AK117, PLX038, mRNA-2752, OTS167PO, PMD-026, X4P-001, BLEX 404, ZEN003694 +Talazoparib, mprime PGG, IPI-549, Trilaciclib, Camrelizumab, HLX10, and others are expected to have a significant impact on the Triple Negative Breast Cancer market in the coming years.
-
In February 2024, Trodelvy (sacituzumab govitecan-hziy) is the first approved antibody-drug conjugate for treating advanced triple-negative breast cancer (TNBC) in adults who have undergone at least two prior treatments for metastatic disease. It is also indicated for pre-treated HR+/HER2- metastatic breast cancer patients and second-line metastatic TNBC patients who have received endocrine-based therapy and at least two other systemic therapies.
-
In June 2023, Gilead Sciences awarded the first “Toward Health Equity for Black People Impacted by Triple Negative Breast Cancer Resource Hub” grant to TOUCH, The Black Breast Cancer Alliance, in partnership with the Triple Negative Breast Cancer Foundation, the American Association for Cancer Research (AACR), and Nueva Vida for their project Black TNBC Matters.
-
In May 2023, The supplemental new drug application (“sNDA”) for Shanghai Junshi Biosciences Co., Ltd.’s anti-PD-1 monoclonal antibody, toripalimab, has been accepted by the National Medical Products Administration. The drug is intended to be used in conjunction with albumin-bound paclitaxel to treat PD-L1 positive (CPS ≥ 1) untreated metastatic or recurrent metastatic triple-negative breast cancer.
-
In May 2023, The announcement was made by Eisai Co., Ltd. and Bliss Biopharmaceutical (Hangzhou) Co., Ltd. on the cooperative development agreement for BB-1701, an antibody-drug conjugate (ADC) with option rights for strategic partnership. In compliance with the terms of the joint development agreement, Eisai will carry out a Phase II clinical trial for breast cancer, pay BlissBio upfront and development milestones, and acquire the option rights to develop and market BB-1701 internationally, with the exception of Greater China (China, Hong Kong, Macau, Taiwan).
-
In May 2023, AML and breast cancer will be treated with gamma-delta T cells (gdTc) thanks to a research collaboration agreement CytoMed Therapeutics Limited signed with The University of Texas MD Anderson Cancer Center (“MD Anderson”) in Houston, Texas. The goal of this partnership is to provide patients with breast cancer and AML with novel, reasonably priced therapy options that address their unmet requirements.
-
In March 2023, The outcomes of the phase II umbrella study FUTURE, which looked at whether the subtyping-based approach may help patients with metastatic TNBC, were revealed. Enrolled in seven parallel arms were 141 patients with a median of three prior lines of therapy in the metastatic scenario.
Triple Negative Breast Cancer Overview
Triple Negative Breast Cancer (TNBC) is characterized by a tumor that has negative levels of estrogen and progesterone (ER/PR), as determined by immunohistochemistry (IHC), and neither immunohistochemistry (IHC) nor fluorescence in situ hybridization (FISH) has detected overexpression of the HER2 gene.
Get a Free Sample PDF Report to know more about Triple Negative Breast Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/triple-negative-breast-cancer-tnbc-pipeline-insight
Emerging Triple Negative Breast Cancer Drugs Under Different Phases of Clinical Development Include:
-
SKB264: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
-
AK117: Akeso Biopharma
-
PLX038: ProLynx
-
mRNA-2752: ModernaTX, Inc.
-
OTS167PO: OncoTherapy Science
-
PMD-026: Phoenix Molecular Designs
-
X4P-001: Abbisko Therapeutics
-
BLEX 404: BioLite, Inc.
-
ZEN003694 +Talazoparib: Zenith Epigenetics
-
mprime PGG: HiberCell, Inc.
-
IPI-549: Infinity Pharmaceuticals
-
Trilaciclib: G1 Therapeutics, Inc
-
Camrelizumab: Jiangsu HengRui Medicine Co., Ltd
-
HLX10: Shanghai Henlius Biotech
Triple Negative Breast Cancer Route of Administration
Triple Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Oral
-
Parenteral
-
Intravenous
-
Subcutaneous
-
Topical
Triple Negative Breast Cancer Molecule Type
Triple Negative Breast Cancer Products have been categorized under various Molecule types, such as
-
Monoclonal Antibody
-
Peptides
-
Polymer
-
Small molecule
-
Gene therapy
Triple Negative Breast Cancer Pipeline Therapeutics Assessment
-
Triple Negative Breast Cancer Assessment by Product Type
-
Triple Negative Breast Cancer By Stage and Product Type
-
Triple Negative Breast Cancer Assessment by Route of Administration
-
Triple Negative Breast Cancer By Stage and Route of Administration
-
Triple Negative Breast Cancer Assessment by Molecule Type
-
Triple Negative Breast Cancer by Stage and Molecule Type
DelveInsight’s Triple Negative Breast Cancer Report covers around 80+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
-
Route of Administration
Further Triple Negative Breast Cancer product details are provided in the report. Download the Triple Negative Breast Cancer pipeline report to learn more about the emerging Triple Negative Breast Cancer therapies
Some of the key companies in the Triple Negative Breast Cancer Therapeutics Market include:
Key companies developing therapies for Triple Negative Breast Cancer are – ModernaTX, Inc, NuGenerex Immuno-Oncology, Pfizer, Jiangsu Alphamab Biopharmaceuticals Co., Ltd., BioLite, Inc., ImmunityBio, Inc., PharmAbcine, Genexine, Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Novartis Pharmaceuticals, Klus Pharma, Ayala Pharmaceuticals, Inc, Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, Akeso Biopharma, Chipscreen Biosciences, OncoPep, Inc., Iovance Biotherapeutics, Inc., SynDevRx, Inc., Hoffmann-La Roche, Celcuity, Inc., Amgen, AstraZeneca, NBE-Therapeutics AG, Fusion Pharmaceuticals, Immutep Limited, and others.
Triple Negative Breast Cancer Pipeline Analysis:
The Triple Negative Breast Cancer pipeline report provides insights into
-
The report provides detailed insights about companies that are developing therapies for the treatment of Triple Negative Breast Cancer with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Triple Negative Breast Cancer Treatment.
-
Triple Negative Breast Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Triple Negative Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Triple Negative Breast Cancer market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Triple Negative Breast Cancer drugs and therapies
Triple Negative Breast Cancer Pipeline Market Drivers
-
Increase in the prevalence of Triple Negative Breast Cancer, increasing Research and Development activities are some of the important factors that are fueling the Triple Negative Breast Cancer Market.
Triple Negative Breast Cancer Pipeline Market Barriers
-
However, high cost of the treatment, side effects associated with the treatment and other factors are creating obstacles in the Triple Negative Breast Cancer Market growth.
Scope of Triple Negative Breast Cancer Pipeline Drug Insight
-
Coverage: Global
-
Key Triple Negative Breast Cancer Companies: Sichuan Kelun-Biotech Biopharmaceutical, Akeso Biopharma, ProLynx, ModernaTX, Inc., OncoTherapy Science, Phoenix Molecular Designs, Abbisko Therapeutics, BioLite, Inc., Zenith Epigenetics, HiberCell, Inc., Infinity Pharmaceuticals, G1 Therapeutics, Inc, Jiangsu HengRui Medicine Co., Ltd, Shanghai Henlius Biotech, and others
-
Key Triple Negative Breast Cancer Therapies: SKB264, AK117, PLX038, mRNA-2752, OTS167PO, PMD-026, X4P-001, BLEX 404, ZEN003694 +Talazoparib, mprime PGG, IPI-549, Trilaciclib, Camrelizumab, HLX10, and others
-
Triple Negative Breast Cancer Therapeutic Assessment: Triple Negative Breast Cancer current marketed and Triple Negative Breast Cancer emerging therapies
-
Triple Negative Breast Cancer Market Dynamics: Triple Negative Breast Cancer market drivers and Triple Negative Breast Cancer market barriers
Request for Sample PDF Report for Triple Negative Breast Cancer Pipeline Assessment and clinical trials
Table of Contents
1. Triple Negative Breast Cancer Report Introduction
2. Triple Negative Breast Cancer Executive Summary
3. Triple Negative Breast Cancer Overview
4. Triple Negative Breast Cancer- Analytical Perspective In-depth Commercial Assessment
5. Triple Negative Breast Cancer Pipeline Therapeutics
6. Triple Negative Breast Cancer Late Stage Products (Phase II/III)
7. Triple Negative Breast Cancer Mid Stage Products (Phase II)
8. Triple Negative Breast Cancer Early Stage Products (Phase I)
9. Triple Negative Breast Cancer Preclinical Stage Products
10. Triple Negative Breast Cancer Therapeutics Assessment
11. Triple Negative Breast Cancer Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Triple Negative Breast Cancer Key Companies
14. Triple Negative Breast Cancer Key Products
15. Triple Negative Breast Cancer Unmet Needs
16 . Triple Negative Breast Cancer Market Drivers and Barriers
17. Triple Negative Breast Cancer Future Perspectives and Conclusion
18. Triple Negative Breast Cancer Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/